Research programme: melanocortin receptor modulators - Palatin Technologies

Drug Profile

Research programme: melanocortin receptor modulators - Palatin Technologies

Alternative Names: PL-8177; PL-8905; PT 18

Latest Information Update: 26 Sep 2016

Price : $50

At a glance

  • Originator Palatin Technologies
  • Class Peptides; Small molecules
  • Mechanism of Action Melanocortin type 1 receptor agonists; Melanocortin type 3 receptor agonists; Melanocortin type 4 receptor agonists; Melanocortin type 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cachexia; Diabetes mellitus; Dry eyes; Erythropoietic protoporphyria; Inflammation; Inflammatory bowel diseases; Kidney disorders; Nephritis; Obesity; Uveitis; Vitiligo

Most Recent Events

  • 20 Sep 2016 Palatin Technologies receives patent allowance for melanocortin-receptor-1 peptides in USA
  • 26 May 2016 Palatin Technologies receives Notice of Allowance for melanocortin receptor-1 (MC1r) peptides in USA
  • 13 Oct 2015 Preclinical trials in Diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top